Lifestyle changes associated with the use of GLP-1 agonists and SGLT2 inhibitors are recommended for the treatment of obesity and T2DM in women, with beneficial effects on weight reduction and metabolic parameters. The gene discussed is SLC5A2; the disease is obesity disorder.